These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 19749027)

  • 1. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    Eur J Endocrinol; 2009 Nov; 161(5):795-8. PubMed ID: 19749027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    J Sex Med; 2007 Sep; 4(5):1479-84. PubMed ID: 17635694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
    Mueller A; Kiesewetter F; Binder H; Beckmann MW; Dittrich R
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3470-5. PubMed ID: 17579193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
    Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
    J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M; Cremers JF; Krallmann C; Kliesch S
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study.
    Uyanik BS; Ari Z; Gümüs B; Yiğitoğlu MR; Arslan T
    Jpn Heart J; 1997 Jan; 38(1):73-82. PubMed ID: 9186283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical and hormonal evaluation of transsexual patients: a longitudinal study.
    Meyer WJ; Webb A; Stuart CA; Finkelstein JW; Lawrence B; Walker PA
    Arch Sex Behav; 1986 Apr; 15(2):121-38. PubMed ID: 3013122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    Kamischke A; Heuermann T; Krüger K; von Eckardstein S; Schellschmidt I; Rübig A; Nieschlag E
    J Clin Endocrinol Metab; 2002 Feb; 87(2):530-9. PubMed ID: 11836281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 12 Months' Treatment with Testosterone Undecanoate on Markers for Erythropoietic Activity and Safety Aspects in Transgender and Cisgender Hypogonadal Men.
    Lethin K; Aardal E; Lood Y; Ekman B; Wahlberg J
    J Appl Lab Med; 2024 Mar; 9(2):223-236. PubMed ID: 38085088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-term use of testosterone enanthate. II. Effects on lipids, high and low density lipoprotein cholesterol and liver function parameters.
    Tyagi A; Rajalakshmi M; Jeyaraj DA; Sharma RS; Bajaj JS
    Int J Androl; 1999 Dec; 22(6):347-55. PubMed ID: 10624603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short-term safety profile of cross-hormonal therapy in trans-male subjects].
    Abdala R; Nagelberg A; Silveira F; Otero P; Mormandi E
    Medicina (B Aires); 2018; 78(6):399-402. PubMed ID: 30504106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
    Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
    Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels.
    Kenny AM; Prestwood KM; Raisz LG
    Endocr Res; 2000 May; 26(2):153-68. PubMed ID: 10921445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
    Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G
    J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of three different testosterone formulations in female-to-male transsexual persons.
    Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC
    J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.